Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer
A biomarker is a biological molecule found in blood, other body [...]
Neoadjuvant axitinib may reduce venous tumour thrombus in kidney cancer
Neoadjuvant treatment is medication that is given before surgery to [...]
Neoadjuvant axitinib may enable partial nephrectomy of complex kidney tumours
Just over half of the patients from a phase 2 [...]
ASCO GU 2022: Neoadjuvant avelumab/axitinib shows promise in kidney cancer
Results from the NeoAvAx clinical trial were presented at the [...]
ASCO 2021: Pembrolizumab plus axitinib continues to improve survival in kidney cancer
The KEYNOTE-426 study of the immune checkpoint inhibitor, pembrolizumab plus [...]
Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer
This Practice Update interview with Dr Monty Pal from City [...]
Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland
The Sottish Medicine Consortium (SMC) have issued a final decision to recommend [...]
Biological markers of response for kidney cancer
To date, a reliable biomarker is yet to be discovered [...]
Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer
The Sottish Medicine Consortium (SMC) have issued a final decision to [...]
